Comparative Pharmacology
Head-to-head clinical analysis: AFEDITAB CR versus CARDENE IN 5 0 DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFEDITAB CR versus CARDENE IN 5 0 DEXTROSE IN PLASTIC CONTAINER.
AFEDITAB CR vs CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.
None Documented
None Documented
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
2 to 4 hours in healthy subjects; increased in hepatic impairment (up to 7 hours) and in elderly. No significant change in renal impairment.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Primarily hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 60-70% of total elimination, with renal excretion of metabolites approximately 30-40%.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker